(4-methyl-benzyl)-thiazol-2-yl-amine | 59775-56-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-methyl-benzyl)-thiazol-2-yl-amine
• 英文别名: N-[(4-methylphenyl)methyl]-1,3-thiazol-2-amine
• CAS: 59775-56-3
• 化学式: C₁₁H₁₂N₂S
• mdl: MFCD11125304
• 分子量: 204.296
• InChiKey: UQJFEKKEEZJLLA-UHFFFAOYSA-N

物化性质

• 熔点：
  120 °C(Solv: methanol (67-56-1))
• 沸点：
  345.7±45.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-methyl-benzyl)-thiazol-2-yl-amine 在 manganese(IV) oxide 作用下， 以 苯 为溶剂， 生成 (4-methyl-benzylidene)-thiazol-2-yl-amine
  参考文献：
  名称：

  Singh,N.; Sethi,P.S., Journal of the Indian Chemical Society, 1975, vol. 52, p. 1079 - 1081

  摘要：

  DOI：
• 作为产物：
  描述：

  (4-methyl-benzylidene)-thiazol-2-yl-amine 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以52%的产率得到(4-methyl-benzyl)-thiazol-2-yl-amine
  参考文献：
  名称：

  Election Impact Mass Spectra of para-Substituted N-Heteroaryl Benzylamines

  摘要：

  The 70 eV electron impact mass spectra of some para-substituted N-heteroaryl benzylamines, synthesized through the corresponding Schiff bases, are reported. Typical fragmentation patterns are discussed with the aid of mass analyzed ion kinetic energy spectra and exact mass measurements. The compounds are relatively stable under electron impact, the molecular ion being the base peak or the second most intense ion in the spectra. The dominating breakdown process is the benzylic cleavage, that gives rise to the base peak in some of the investigated compounds and to the second intense peak in others.

  DOI：

  10.3987/com-93-s16

文献信息

• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Kubota Hideki

  公开号：US20080227785A1

  公开（公告）日：2008-09-18

  This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

  本发明涉及一种以BEC 1钾离子通道抑制剂作为活性成分的抗痴呆剂。已经证明，BEC 1钾离子通道抑制剂具有改善学习障碍的作用，并且作为预防或治疗剂是有用的，尤其是对于BEC 1钾离子通道与之相关的疾病，如痴呆症。例如，通过体内试验证实，BEC 1钾离子通道抑制剂具有改善学习障碍的作用。此外，还发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾离子通道抑制作用。
• DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS
  申请人：AMGEN INC.

  公开号：US20150057271A1

  公开（公告）日：2015-02-26

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了I式化合物或其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav1.7。这些化合物对于治疗可通过钠通道抑制治疗的疾病如疼痛症状是有用的。还提供了含有本发明化合物的药物组合物。
• 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Ortho-McNeil-Janssen Pharmaceuticals, Inc.

  公开号：EP2426125A1

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是符合式 (I) 的新型吡啶酮衍生物 其中所有基团在申请和权利要求中均有定义。根据本发明的化合物是代谢受体-亚型 2（"mGluR2"）的正异位调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢受体的 mGluR2 亚型的疾病。特别是，这类疾病是选自焦虑症、精神分裂症、偏头痛、抑郁症和癫痫组的中枢神经系统疾病。本发明还涉及药物组合物和制备此类化合物及组合物的工艺，以及使用此类化合物预防和治疗涉及 mGluR2 的此类疾病。
• SINGH N.; SETHI P. S., J. INDIAN CHEM. SOC. <JICS-AH>, 1975, 52, NO 11, 1079-1081
  作者：SINGH N.、 SETHI P. S.

  DOI：——

  日期：——
• 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS
  申请人：Imogai Hassan Julien

  公开号：US20100166655A1

  公开（公告）日：2010-07-01

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.